Kadimastem - Stem Cell to Cure Diseases

Regenerative Medicine > Diabetes

Diabetes mellitus is a chronic disorder characterized by symptoms of high blood glucose levels and glucose intolerance, due to insulin deficiency, impaired effectiveness of insulin action, or both.

Diabetes is classified on the basis of cause and clinical presentation of the disorder into two major types:  type 1 and type 2 diabetes.

  • Type 1 diabetes (Type 1 DM) - is an immune mediated disease in which the pancreatic islets are destroyed, causing deficiency in insulin production and secretion. Type 1 DM currently requires daily glucose monitoring and injection of exogenous insulin.
  • Type 2 diabetes (Type 2 DM)- results from insulin resistance, a condition in which cells of the body fail to use insulin properly. Type 2 DM patients may also suffer from insulin deficiency.

The number of patients with diabetes was estimated to be over 366 million worldwide in 2011, and is projected to be more than 552 million in 2030.  The American Diabetes Association (ADA) estimated the total annual costs of diabetes to be US$223.5 billion (in the US alone). The global cost is estimated to be US$465 billion annually and will grow to about US$510 billion by 2030.

Kadimastem’s Human Pluripotent Stem Cell-based (hPSC) solution
Kadimastem’s hPSC-based technology for diabetes therapy is based on stepwise differentiation of human embryonic stem cells (hESCs) towards insulin producing beta cells, and glucagon producing alpha cells arranged in islet-like clusters.

The company’s proprietary technology is a combination of a specific differentiation process with highly effective purification capabilities of the islet-like clusters. Starting from large scale hESC-cultures, Kadimastem’s process drives the cells through ordered developmental stages, towards pancreatic endocrine cells (see Figure below).

The mature pancreatic endocrine cells are then isolated by a method based on immune-affinity, followed by re-aggregation into functional islet-like clusters comprised of insulin-producing cells (see Figure below), and glucagon-producing cells.

Kadimastem’s islet-like clusters contain high insulin mRNA as well as insulin (c-Peptide) contents. These islet-like clusters also demonstrat functional glucose-dependent secretion of insulin. The company’s method has allowed the formation of clusters in a biomatrix, while its preclinical program includes further development of encapsulation technologies to protect the cells from the patient's immune system.

Kadimastem’s regenerative medicine program is designed to allow large scale production of encapsulated devices which will be implanted in patients, constantly sensing blood glucose levels and secret insulin accordingly.

The company’s solution is designed to replace the exhausting daily blood glucose monitoring and insulin injections performed by millions of Diabetes patients worldwide. In addition, this solution can potentially prevent risks of hypoglycemia as well as the long term secondary manifestations of diabetes, such as: Renal failure, neuropathies, cardiovascular complications and glaucoma.